Biological properties of melanoma and endothelial cells after plasmid amep gene electrotransfer depend on integrin quantity on cells

Journal of Membrane Biology

Volumn 246, Issue 11, 2013, Pages 803-819

  Bosnjak, Masa ^a   Prosen, Lara ^b   Dolinsek, Tanja ^a   Blagus, Tanja ^a   Markelc, Bostjan ^a   Cemazar, Maja ^a,c   Bouquet, Celine ^d   Sersa, Gregor ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b KOLEKTOR GROUP D O O   (Slovenia)

^c UNIVERSITY OF PRIMORSKA   (Slovenia)

^d BioAlliance Pharma   (France)

Author keywords

Antiangiogenic; Gene electrotransfer; Human endothelial cells; Integrins; Murine melanoma cells; Plasmid AMEP

Indexed keywords

ANTIANGIOGENIC METARGIDIN PEPTIDE; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; FIBRONECTIN; INTEGRIN; MATRIGEL; PLASMID DNA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ELECTROPORATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; METASTASIS; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL;

MURINAE;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ELECTROPORATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; INTEGRINS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; TRANSFECTION;

EID: 84887996453     PISSN: 00222631     EISSN: 14321424     Source Type: Journal    
DOI: 10.1007/s00232-013-9550-y     Document Type: Article

References (30)

1. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111-118
2. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA (1990) Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 50:6757-6764
3. Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8:604-617
4. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264(5158):569-571
5. Campana LG, Valpione S, Falci C, Mocellin S, Basso M, Corti L, Balestrieri N, Marchet A, Rossi CR (2012) The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Treat 134:1169-1178
6. Cemazar M, Wilson I, Dachs GU, Tozer GM, Sersa G (2004) Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy - spatial and time dependent distribution. BMC Cancer 4:81
7. Cemazar M, Jarm T, Sersa G (2010) Cancer electrogene therapy with interleukin-12. Curr Gene Ther 10:300-311
8. Danhier F, Le Breton A, Preat V (2012) RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 9:2961-2973
9. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896-5903
10. Daugimont L, Vandermeulen G, Defresne F, Bouzin C, Mir LM, Bouquet C, Feron O, Preat V (2011) Antitumoral and antimetastatic effect of antiangiogenic plasmids in B16 melanoma: higher efficiency of the recombinant disintegrin domain of ADAM 15. Eur J Pharm Biopharm 78:314-319
11. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22
12. Gehl J (2008) Electroporation for drug and gene delivery in the clinic: doctors go electric. Methods Mol Biol 423:351-359
13. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
14. Kuphal S, Bauer R, Bosserhoff AK (2005) Integrin signaling in malignant melanoma. Cancer Metast Rev 24:195-222
15. Linnert M, Iversen HK, Gehl J (2012) Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy. Radiol Oncol 46:271-278
16. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D (2013) Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 39:4-16
17. Markelc B, Bellard E, Sersa G, Pelofy S, Teissie J, Coer A, Golzio M, Cemazar M (2012) In vivo molecular imaging and histological analysis of changes induced by electric pulses used for plasmid DNA electrotransfer to the skin: a study in a dorsal window chamber in mice. J Membr Biol 245:545-554
18. Miklavcic D, Sersa G, Brecelj E, Gehl J, Soden D, Bianchi G, Ruggieri P, Rossi CR, Campana LG, Jarm T (2012) Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med Biol Eng Comput 50:1213-1225
19. Mizejewski GJ (1999) Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222:124-138
20. Nath D, Slocombe PM, Stephens PE, Warn A, Hutchinson GR, Yamada KM, Docherty AJ, Murphy G (1999) Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci 112(Pt 4):579-587
21. Niemisto A, Dunmire V, Yli-Harja O, Zhang W, Shmulevich I (2005) Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imaging 24:549-553
22. Ohno R (2006) Treatment of chronic myeloid leukemia with imatinib mesylate. Int J Clin Oncol 11:176-183
23. Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, Blagus T, Cemazar M, Sersa G (2012) Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol 46:302-311
24. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M (2008) Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 34:232-240
25. Spanggaard I, Snoj M, Cavalcanti A, Bouquet C, Sersa G, Robert C, Vasseur B, Attali P, Mir LM, Gehl J (2012) Proof of concept of gene therapy using plasmid AMEP in disseminated melanoma: safety and efficacy results of phase I first-in-man study. In: Abstracts of the 37th ESMO Congress, Vienna, Austria, September 28-October 2, 2012. Ann Oncol 23(Suppl 9)
26. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23:651-661
27. Trochon-Joseph V, Martel-Renoir D, Mir LM, Thomaidis A, Opolon P, Connault E, Li H, Grenet C, Fauvel-Lafeve F, Soria J, Legrand C, Soria C, Perricaudet M, Lu H (2004) Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 64:2062-2069
28. Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D 4th, Schuchter L, Van Belle TJ, Albelda S, Tahin P, Herlyn M, Elder DE (1999) Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 30:562-567
29. Varner JA, Cheresh DA (1996) Integrins and cancer. Curr Opin Cell Biol 8:724-730
30. Zhang XP, Kamata T, Yokoyama K, Puzon-McLaughlin W, Takada Y (1998) Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J Biol Chem 273:7345-7350